Amundi Acquires 36,968 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Amundi increased its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 188.2% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 56,609 shares of the biopharmaceutical company's stock after buying an additional 36,968 shares during the period. Amundi's holdings in Catalyst Pharmaceuticals were worth $1,291,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in CPRX. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $27,000. Larson Financial Group LLC grew its stake in shares of Catalyst Pharmaceuticals by 27,218.2% in the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 2,994 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $65,000. KBC Group NV grew its stake in shares of Catalyst Pharmaceuticals by 48.8% in the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after buying an additional 1,542 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. purchased a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter worth approximately $134,000. Hedge funds and other institutional investors own 79.22% of the company's stock.

Insider Transactions at Catalyst Pharmaceuticals

In related news, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares of the company's stock, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This represents a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several brokerages have commented on CPRX. HC Wainwright reiterated a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. Stephens reiterated an "overweight" rating and set a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird increased their target price on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Monday, February 3rd. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $32.50.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock traded up $1.07 on Friday, reaching $24.23. The stock had a trading volume of 4,923,840 shares, compared to its average volume of 1,054,828. The stock has a market cap of $2.94 billion, a P/E ratio of 20.53, a price-to-earnings-growth ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $24.64. The company has a 50 day simple moving average of $22.39 and a 200 day simple moving average of $21.61.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.